1. Legal requirement: Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
Management of serious breaches of clinical trials authorised in the Europe Union (EU)/ European Economic Area (EEA) is defined by Regulation (EU) No 536/2014, which states in Article 52:
“1. The sponsor shall notify the Member States concerned about a serious breach of this Regulation or of the version of the protocol applicable at the time of the breach through the EU portal without undue delay but not later than seven days of becoming aware of that breach.
2. For the purposes of this Article, a ‘serious breach’ means a breach likely to affect to a significant degree the safety and rights of a subject or the reliability and robustness of the data generated in the clinical trial.”
© European Medicines Agency, 2021
Clinical Research News
Upcoming Clinical Research Training and Conferences
-
on demandACROSS Global Training AcademyOnline
-
29 September 2023 – 02 October 2024SCDM (Society of Clinical Data Management)United States
-
21 – 23 May 2024InformaBelgium
-
03 – 04 June 2024The Society for Clinical Research Sites (SCRS)United States
-
16 – 17 July 2024The Society for Clinical Research Sites (SCRS)Australia
-
27 September – 29 October 2024The Society for Clinical Research Sites (SCRS)United States
即将进行的临床试验
-
University of California, San FranciscoAmerican Society of Transplantation招聘中
-
University of California, San DiegoMayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Yale University; Brigham and Women... 和其他合作者招聘中
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); New Mexico State University; National Cancer Institute Center...尚未招聘
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol Foundation招聘中
-
Centre Hospitalier Universitaire de Saint EtienneLEO Pharma; Ligue contre le cancer, France; Diagnostica Stago尚未招聘